211555-04-3

Basic information

• Product Name: JAK3 Inhibitor
• Synonyms: JAK3 Inhibitor;2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol;Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-;4-(3'-Bromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline WHI-P 154;2-Bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol
• CAS NO: 211555-04-3
• Molecular Formula: C16H14BrN3O3
• Molecular Weight: 376.20466
• EINECS: -0
• Product Categories: Inhibitor;JAK/STAT;Inhibitors;JAK;STAT
• Mol File: 211555-04-3.mol
• Article Data: 0

Chemical Properties

• Melting Point: 230 °C
• Boiling Point: 470.3±45.0 °C(Predicted)
• Appearance: white to brown/
• Density: 1.576±0.06 g/cm3(Predicted)
• Storage Temp.: Store at RT
• Solubility: DMSO: soluble1mg/mL, clear (warmed)
• PKA: 8.57±0.31(Predicted)
• CAS DataBase Reference: JAK3 Inhibitor(CAS DataBase Reference)
• NIST Chemistry Reference: JAK3 Inhibitor(211555-04-3)
• EPA Substance Registry System: JAK3 Inhibitor(211555-04-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 211555-04-3(Hazardous Substances Data)

Usage

Description

JAK3 Inhibitor, specifically WHI-P154, is a quinazoline derivative that functions as an immunosuppressive agent. It selectively inhibits JAK3, a non-receptor tyrosine kinase, with an IC50 of 1.8 μM, while also exhibiting inhibitory effects on other kinases such as EGFR, VEGFR, Abl, Lck, and Src. WHI-P154 has demonstrated cytotoxicity against human glioblastoma cells and has been utilized to induce the differentiation of neuronal precursor cells.

Uses

Used in Pharmaceutical Industry:
JAK3 Inhibitor is used as an immunosuppressive agent for its ability to selectively inhibit JAK3, making it a potential candidate for treating various immune-related disorders and conditions.
Used in Oncology:
JAK3 Inhibitor is used as an antileukemic agent for its apoptosis-inducing activity, targeting and suppressing the growth of leukemia cells.
Used in Cancer Treatment:
JAK3 Inhibitor is used as a cytotoxic agent for human glioblastoma cells, with an IC50 of 813 nM, contributing to the inhibition of tumor growth and progression.
Used in Neurology:
JAK3 Inhibitor is used to induce the differentiation of neuronal precursor cells, potentially aiding in the treatment and understanding of neurological disorders and injuries.

Biochem/physiol Actions

WHI-P154 is a specific inhibitor of JAK3 (IC50 = 1.8 μM) with no inhibitory activity against JAK1 or JAK2. WHI-P154 enhances myogenic differentiation of C2C12 mouse myoblast cells, and induces differentiation of neural progenitor cells. The compound WHI-P154 dose dependently inhibits expression of iNOS and NO production in LPS-challenged macrophages.

in vitro

kinase assays show that whi-p154 is not a specific inhibitor. besides jak3, it also inhibits many other kinases, including egfr, abl, lck, src and vegfr. whi-p154 inhibits egfr with ic50 value of 4nm. the specificity of whi-p154 has not been shown in cell-based assays either [1].

references

[1] changelian ps, moshinsky d, kuhn cf, flanagan me, munchhof mj, harris tm, whipple da, doty jl, sun j, kent cr, magnuson ks, perregaux dg, sawyer ps, kudlacz em. the specificity of jak3 kinase inhibitors. blood. 2008 feb 15;111(4):2155-7. [2] narla rk, liu xp, myers de, uckun fm. 4-(3'-bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. clin cancer res. 1998 jun;4(6):1405-14.